Effects of Eptazocine, a Novel Analgesic, on KCN-Induced Changes in the Cerebral Contents of Glycolytic Metabolites and High-Energy Phosphates in Mice

Tomoaki TAMURA, Toshietsu TANIGUCHI, Tetsuo MIYAMOTO, Masaru AOKI and Isami WAKI

Central Research Laboratories, Nihon Iyakuhin Kogyo Co., Ltd., 205-1 Shimoumezawa, Namerikawa, Toyama 936, Japan

Accepted July 10, 1990

Abstract—Effects of eptazocine on cerebral metabolic changes due to a sublethal dose of KCN were investigated in mice. KCN (2 mg/kg, i.v.) induced a temporary loss of consciousness being moderated by eptazocine (1–10 mg/kg) in a dose-dependent manner. The KCN injection decreased the contents of phosphocreatine (PCr), ATP and glucose and increased the contents of AMP and lactate, resulting in a 34% decrease in energy charge potential (ECP) and an increase in lactate/pyruvate (L/P) ratio. Such changes were improved by eptazocine (10 mg/kg) and EKC (3 mg/kg), but not by pentazocine (10 mg/kg) and morphine (3 mg/kg), and the improving effect of eptazocine was completely inhibited by MR-2266 (3 mg/kg), a relatively selective opioid \( \kappa \)-receptor antagonist. On the other hand, eptazocine (3, 10 mg/kg) was found to increase the glucose content in normal mice, but not to give significant changes in the contents of glycolytic metabolites and high-energy phosphates. These results suggest that eptazocine may improve anoxic changes in cerebral energy metabolism.

Eptazocine (\( \beta \)-1,4-dimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazonine) has been regarded as such an opioid \( \kappa \)-antagonist–\( \delta \)-agonist, like pentazocine (1–3). In our previous study (4), analgesic doses of eptazocine significantly prolonged the survival time of mice subjected to either hypobaric hypoxia or KCN-induced cytotoxic anoxia in a dose-dependent manner; and the effect was inhibited by MR-2266, a relatively selective opioid \( \kappa \)-receptor antagonist, more potently than by naloxone, suggesting that eptazocine may elicit its anti-anoxic action via its binding with opioid \( \kappa \)-receptors. Beneficial effects of opioid \( \kappa \)-agonists against ischemic neurological deficits in experimental animals were reported (5–7). Actions of these compounds, however, on cerebral energy metabolism, which is extremely sensitive to anoxic and ischemic treatments, have not been elucidated. It is of great interest to determine whether eptazocine may improve anoxic changes in cerebral energy metabolism through opioid \( \kappa \)-receptors. In the present study, effect of eptazocine on cerebral metabolic changes due to an injection of a sublethal dose of KCN (2 mg/kg, i.v.) were investigated in comparison with those of typical opioid compounds.

Materials and Methods

Animals: Male mice of the ddY strain (Nihon SLC Co., Ltd., Shizuoka), weighing 26–32 g, were used. They were housed in an air-conditioned room at 23±1°C and were given standard diet (MF, Oriental Yeast Co., Ltd., Tokyo) and tap water ad libitum before being used.

Drugs: Eptazocine hydrobromide, ethylketocyclazocine methanesulfonate (EKC) and (−)-2-[(3-furylmethyl)-5,9-diethyl-2'-hydroxy-6,7-benzomorphan (MR-2266) were synthetized in our laboratories. Pentazocine hydrochloride and morphine hydrochloride...
were purchased from Sankyo Co., Ltd. (Tokyo); glucose-6-phosphate (G6P), fructose-1,6-diphosphate (FDP), hexokinase, G6P dehydrogenase, pyruvate kinase, myokinase, amyloglucosidase, adenine dinucleotides and adenosine phosphates were from Sigma Chemical Co. (St. Louis, MO, U.S.A.); and lactate dehydrogenase and creatine kinase were from Boehringer Mannheim Yamanouchi Co., Ltd. (Tokyo). Other chemicals were obtained from Wako Pure Chemical Industries, Ltd. (Osaka). MR-2266 was dissolved in 100 mM methanesulphonate and diluted with distilled water. Other test drugs were dissolved in physiological saline.

Loss of consciousness due to a KCN injection: Mice pretreated with test drugs were injected with KCN (2 mg/10 ml/kg) at the rate of 0.6 ml/10 sec via the tail veins, and durations of loss of the righting reflex and spontaneous movement were measured, respectively.

Determination of glycolytic metabolites and high-energy phosphates: Mice pretreated with test drugs and/or KCN (2 mg/kg, i.v.) were sacrificed by microwave irradiation (TMW-6402; 5 kW, 1.4 sec, Toshiba). The whole brains were taken out after the heads were cooled in ice-cold water. The brains were weighed, and homogenized in 3.5 ml of 2 N perchloric acid. After each portion of the homogenate was taken for glycogen analysis (8), the residuals were allowed to stand in ice-cold water for 30 min and then centrifuged at 20,000×g for 15 min. The supernatants were neutralized with 6 N K₂CO₃, centrifuged at 1,000×g for 10 min, and used for the assays. PCr, ATP, glucose, pyruvate and lactate were analyzed according to the enzymatic fluorometric techniques as described by Lowry et al. (9); and G6P, FDP, ADP and AMP were determined by the UV-methods of Bergmeyer (10–12). The energy state of each tissue was expressed as the energy charge potential (ECP) of the adenine nucleotide pool according to Atkinson (13): ECP=([ATP]+0.5(ADP))/([ATP]+(ADP)+(AMP)].

Statistical analysis: Values were represented as the mean±S.E., and one-way analysis of variance followed by Student’s t-test or the Aspin-Welch t-test were carried out.

Results

Effect of eptazocine on loss of consciousness due to a KCN injection: An injection of KCN (2 mg/kg, i.v.) to saline-treated mice immediately induced clonic convulsion, followed by loss of the righting reflex with a respiratory failure; and about 342 sec later, the mice had spontaneous movement again. Effects of eptazocine (1–10 mg/kg, i.p.) on KCN-induced loss of the righting reflex and spontaneous movement were examined, and the results are shown in Table 1. Eptazocine (10 mg/kg) shortened the duration of loss of consciousness.

Effects of eptazocine and opioid compounds on changes in the contents of cerebral metabolites due to the KCN injection: The preliminary experiments showed that the cerebral ATP content in mice decreased to 82, 55 and 74% of the normal value 45, 90 and 180 sec after the KCN injection, respectively. Therefore, the contents of cerebral metabolites, ECP and L/P ratio were determined 90 sec after the KCN injection (Tables 2 and 3). The cerebral contents of PCr and ATP were decreased, and the AMP content

| Treatment | Dose (mg/kg, i.p.) | RR time (sec) | SM time (sec) |
|-----------|-------------------|---------------|---------------|
| Control   | 0                 | 260±28        | 342±30        |
| Eptazocine| 1                 | 233±25        | 290±25        |
|           | 3                 | 188±22        | 267±25        |
|           | 10                | 181±11*       | 248±24*       |

Each value represents the mean±S.E. (n=8). *P<0.05, compared with each control value. KCN (2 mg/kg, i.v.) was injected 30 min after administration of saline (control) or eptazocine. RR time: duration of loss of righting reflex. SM time: duration of loss of spontaneous movement.
Table 2. Effects of eptazocine, EKC, pentazocine and morphine on KCN-induced changes in the cerebral contents of PCr, ATP, ADP and AMP in mice

| Treatment     | Dose (mg/kg, i.p.) | Contents in cerebral tissue (µmole/g) | ECP          |
|---------------|--------------------|--------------------------------------|--------------|
|               |                    | PCr                                 | ATP          | ADP          | AMP          |              |
| Normal        | —                  | 5.30±0.18**                         | 2.53±0.04**  | 0.53±0.03    | 0.06±0.01**  | 0.897±0.005**|
| Control       | —                  | 2.70±0.28                           | 1.26±0.14    | 0.59±0.05    | 0.75±0.06    | 0.590±0.034  |
| Eptazocine    | 10                 | 4.43±0.26**                         | 2.07±0.17**  | 0.56±0.04    | 0.36±0.13*   | 0.790±0.049**|
| EKC           | 3                  | 3.60±0.27*                          | 2.01±0.18**  | 0.55±0.01    | 0.31±0.10**  | 0.788±0.043**|
| Pentazocine   | 10                 | 2.43±0.40                           | 1.44±0.21    | 0.57±0.02    | 0.68±0.16    | 0.635±0.069  |
| Morphine      | 3                  | 2.34±0.26                           | 1.30±0.18    | 0.82±0.04    | 0.83±0.15    | 0.584±0.060  |

Each value represents the mean±S.E. (n=7). *P<0.05, **P<0.01, compared with each control value. KCN (2 mg/kg, i.v.) was injected 30 min after administration of saline (control) or test drugs. Mice received microwave irradiation (5 kW, 1.4 sec) 90 sec after the KCN injection. PCr: phosphocreatine ECP: energy charge potential.

Table 3. Effects of eptazocine, EKC, pentazocine and morphine on KCN-induced changes in the cerebral contents of glucose, lactate and pyruvate in mice

| Treatment     | Dose (mg/kg, i.p.) | Contents in cerebral tissue (µmole/g) | L/P          |
|---------------|--------------------|--------------------------------------|--------------|
|               |                    | Glucose                | Lactate      | Pyruvate     |              |
| Normal        | —                  | 1.84±0.09**            | 1.24±0.13**  | 0.091±0.008  | 13.8±0.6**   |
| Control       | —                  | 0.45±0.03              | 7.92±0.20    | 0.109±0.005  | 73.5±3.3     |
| Eptazocine    | 10                 | 1.09±0.12**            | 6.22±0.40**  | 0.148±0.015  | 45.5±5.9**   |
| EKC           | 3                  | 0.77±0.04**            | 7.43±0.32    | 0.145±0.015  | 54.6±5.7*    |
| Pentazocine   | 10                 | 0.39±0.03              | 8.47±0.37    | 0.123±0.005  | 68.9±2.5     |
| Morphine      | 3                  | 0.44±0.03              | 8.02±0.26    | 0.115±0.006  | 71.8±6.7     |

Each value represents the mean±S.E. (n=7). *P<0.05, **P<0.01, compared with each control value. KCN (2 mg/kg, i.v.) was injected 30 min after administration of saline (control) or test drugs. Mice received microwave irradiation (5 kW, 1.4 sec) 90 sec after the KCN injection. L/P: lactate/pyruvate ratio.
was increased, resulting in a decrease in ECP. The cerebral anoxic treatment also showed a decrease in the glucose content and increases in the lactate content and L/P ratio. These KCN-induced metabolic changes were prevented by a 30 min-pretreatment with eptazocine (10 mg/kg) or EKC (3 mg/kg), whereas morphine (3 mg/kg) and pentazocine (10 mg/kg) did not show such effects. MR-2266 was used to determine whether such effects of eptazocine were mediated via opioid \(\kappa\)-receptors or not. MR-2266 of 3 mg/kg, which showed no significant effect on the cerebral energy metabolism, completely inhibited the effects of eptazocine (Fig. 1).

![Graphs of Glucose, ECP, Lactate, and L/P content](image)

**Fig. 1.** Antagonistic effect of MR-2266 on the improving effect of eptazocine against KCN-induced cerebral metabolic changes in mice. Each column with vertical bars represents the mean\(\pm\)S.E. (n=6). *P<0.05, **P<0.01, compared with each KCN alone value. *P<0.05, **P<0.01, compared with each (KCN plus eptazocine) value. Eptazocine and MR-2266 were administered i.p. at 20 and 30 min before a KCN (2 mg/kg, i.v.) injection, respectively. Mice received microwave irradiation (5 kW, 1.4 sec) 90 sec after the KCN injection.

Effects of eptazocine and opioid compounds on the contents of cerebral glycolic metabolites in normal mice: We attempted to determine whether the above-mentioned effects of eptazocine are shown in normal mice. Tables 4 and 5 show that a 30-min pretreatment with eptazocine induced an increase in the glucose content but no changes in the contents of glycogen, G6P, FDP, PCr, ATP, lactate and pyruvate. An increase in the glucose content was also shown in the case of EKC (3 mg/kg) and morphine (3 mg/kg).

Discussion

Cyanide inhibits the terminal oxidase enzyme cytochrome oxidase in the cerebral tissue, resulting in disorder of the mitochondrial energy-producing systems (14–16), and such a cyanide-induced acute cerebral anoxia in animals has been widely used for the evaluation of cerebral protective drugs (17–19). In the previous report (4), we showed that eptazocine as well as EKC, a typical opioid \(\kappa\)-agonist, prolonged the survival time of mice subjected to a lethal dose of KCN (3 mg/kg, i.v.). In this study, a sublethal dose of KCN (2 mg/kg, i.v.) was tested, and KCN-induced temporary loss of consciousness was shown to be overcome by the pretreatment with eptazocine. In order to elucidate whether such an effect of eptazocine can be at-
Table 4. Effects of optazocine, EKC, pentazocine and morphine on the cerebral contents of glycogen, glucose, G6P and FDP in mice

| Treatment     | Dose (mg/kg, i.p.) | Glycogen (μmole/g) | Glucose (μmole/g) | G6P (μmole/g) | FDP (μmole/g) |
|---------------|--------------------|--------------------|------------------|--------------|--------------|
| Normal        | —                  | 2.42±0.15          | 1.73±0.10        | 0.135±0.004  | 0.134±0.014  |
| Eptazocine    | 3                  | 2.20±0.12          | 2.14±0.10*       | 0.137±0.004  | 0.154±0.014  |
|               | 10                 | 2.09±0.12          | 2.49±0.07**      | 0.138±0.004  | 0.131±0.014  |
| EKC           | 3                  | 2.50±0.14          | 2.76±0.14**      | 0.140±0.006  | 0.131±0.012  |
| Pentazocine   | 10                 | 2.28±0.09          | 1.79±0.07        | 0.136±0.004  | 0.160±0.012  |
| Morphine      | 3                  | 2.28±0.13          | 2.05±0.10*       | 0.136±0.003  | 0.114±0.010  |

Each value represents the mean±S.E. (n=7). *P<0.05, **P<0.01, compared with each normal value. Mice received microwave irradiation (5 kW, 1.4 sec) 30 min after administration of test drugs. G6P: glucose-6-phosphate. FDP: fructose-1,6-diphosphate.

Table 5. Effects of optazocine, EKC, pentazocine and morphine on the cerebral contents of PCr, ATP, lactate and pyruvate in mice

| Treatment     | Dose (mg/kg, i.p.) | PCr (μmole/g) | ATP (μmole/g) | Lactate (μmole/g) | Pyruvate (μmole/g) | L/P |
|---------------|--------------------|---------------|---------------|------------------|------------------|-----|
| Normal        | —                  | 5.04±0.16     | 2.43±0.06     | 1.29±0.04        | 0.144±0.013      | 9.80±1.54 |
| Eptazocine    | 3                  | 4.48±0.50     | 2.37±0.11     | 1.09±0.01        | 0.134±0.007      | 8.09±0.64 |
|               | 10                 | 5.73±0.34     | 2.64±0.08     | 1.17±0.06        | 0.149±0.010      | 7.97±0.47 |
| EKC           | 3                  | 4.49±0.46     | 2.43±0.09     | 1.18±0.06        | 0.137±0.007      | 8.80±0.69 |
| Pentazocine   | 10                 | 5.23±0.59     | 2.60±0.06     | 1.42±0.08        | 0.152±0.012      | 9.84±1.24 |
| Morphine      | 3                  | 5.39±0.30     | 2.59±0.06     | 1.34±0.12        | 0.154±0.011      | 8.92±1.08 |

Each value represents the mean±S.E. (n=7). Mice received microwave irradiation (5 kW, 1.4 sec) 30 min after administration of test drugs. L/P: lactate/pyruvate ratio.
tributed to an improvement by eptazocine of cerebral energy metabolism. KCN-induced changes in cerebral energy metabolism were first investigated using biochemical techniques. At 90 sec after the KCN injection, the cerebral tissue was in a severe anoxic state, since ECP, which is a parameter of the cerebral energy state, decreased from 0.897 to 0.590. The L/P ratio also increased from 13.8 to 73.5, indicating an increase in the anaerobic glycolytic rate. These KCN-induced changes in cerebral energy metabolism were prevented by eptazocine (10 mg/kg), suggesting an improving action of eptazocine on the cerebral glycolytic pathway or a mitochondrial respiratory function. The action of eptazocine seems likely to be mediated via opioid \( \kappa \)-receptors, because it was completely inhibited by MR-2266 (3 mg/kg), which has been reported to be a relatively selective \( \kappa \)-receptor antagonist rather than a \( \mu \)-antagonist (21). Moreover, EKC showed a similar effect, whereas morphine (3 mg/kg) and pentazocine (10 mg/kg) had no significant effect, supporting our previous report concerning prolonged effects on the survival time in mice subjected to cerebral anoxia (4).

High doses of eptazocine showed non-specific inhibitory actions on the central nervous system in mice (22). Barbiturates (23–25), diazepam (26) and nizofenone (27) induced anti-anoxic effects through reducing the cerebral metabolic rate. The administration of eptazocine at 3 or 10 mg/kg to normal mice was found to increase the cerebral glucose content, but this caused no significant changes in the contents of glycolytic intermediates. At present, the mechanism by which eptazocine increased the glucose content is not clear, but eptazocine seems to show no inhibitory effect on the cerebral glycolytic metabolism, different from what is reported in the case of the above-mentioned drugs. In addition, EKC and morphine also increased the glucose content. It remains to be determined whether such an glucose increase can contribute to improvement of the anoxic changes.

In conclusion, the protective effects of eptazocine on cerebral anoxia may be attributed to the improvement of anoxic changes in cerebral energy metabolism.

References

1 Nabeshima, T., Yamada, S., Yamaguchi, K., Matsuno, K., Kameyama, T., Sakakibara, S. and Matsumoto, S.: Pharmacological action of eptazocine (\(-1,4\)-dimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1H-4-benzazepine). (IV) Narcotic agonist and antagonist-action of eptazocine. Folia Pharmacol. Japon. 81, 411–420 (1983) (Abs. in English)

2 Nabeshima, T., Matsuno, K., Kamei, H. and Kameyama, T.: The interaction of eptazocine, a novel analgesic, with opioid receptors. Res. Commun. Chem. Pathol. Pharmacol. 48, 173–181 (1985)

3 Tamura, T., Ogawa, J., Taniguchi, T. and Waki, I.: Preferential action of eptazocine, a novel analgesic, with opioid receptors in isolated guinea pig ileum and mouse vas deferens preparations. Folia Pharmacol. Japon. 95, 41–46 (1990) (Abs. in English)

4 Tamura, T., Taniguchi, T., Aoki, M. and Waki, I.: Protective effect of eptazocine, a novel analgesic, against cerebral hypoxia-anoxia in mice. Folia Pharmacol. Japon. 95, 167–175 (1990) (Abs. in English)

5 Tang, A.H.: Protection from cerebral ischemia by U-50,488E, a specific kappa opioid analgesic agent. Life Sci. 37, 1475–1482 (1985)

6 Baskin, D.S., Kuroda, H., Hosobuchi, Y. and Lee, N.M.: Treatment of stroke with opiate antagonists—Effects of exogenous antagonists and dynorphin 1-13. Neuropeptides 5, 307–310 (1985)

7 Baskin, D.S., Hosobuchi, Y., Loh, H.H. and Lee, N.M.: Dynorphin (1-13) improves survival in cats with focal cerebral ischaemia. Nature 312, 551–552 (1984)

8 Keppler, D. and Decker, K.: Glycogen. In Methods of Enzymatic Analysis (Third Edi.), Edited by Bergmeyer, H.U., Vol. 6, p. 11–18, VCH Verlagsgesellschaft, Weinheim (1984)

9 Lowry, O.H., Passonneau, J.V., Hasselberger, F.X. and Schulz, D.W.: Effect of ischaemia on known substrates and cofactors of the glycolytic pathway in brain. J. Biol. Chem. 239, 18–30 (1964)

10 Michal, G.: D-Glucose 6-phosphate and D-fructose 6-phosphate. In Methods of Enzymatic Analysis (Third Edi.), Edited by Bergmeyer, H.U., Vol. 6, p. 191–198, VCH Verlagsgesellschaft, Weinheim (1984)

11 Schaftingen, E.V.: D-Fructose 2,6-bisphosphate, in Methods of Enzymatic Analysis (Third Edi.), Edited by Bergmeyer, H.U., Vol. 6, p. 335–341,
VCH Verlagsgesellschaft, Weinheim (1984)

12 Jaworek, D. and Welsch, J.: Adenosine 5'-diphosphate and adenosine 5'-monophosphate. In Methods of Enzymatic Analysis (Third Ed.), Edited by Bergmeyer, H.U., Vol. 7, p. 365–371, VCH Verlagsgesellschaft, Weinheim (1985)

13 Atkinson, D.E.: The energy charge of the adenylate pool as a regulatory parameter. Interaction with feedback modifiers. Biochemistry 7, 4030–4034 (1968)

14 Schubert, J. and Brill, W.A.: Antagonism of experimental cyanide toxicity in relation to the in vitro activity of cytochrome oxidase. J. Pharmacol. Exp. Ther. 162, 362–359 (1968)

15 Way, J.L.: Cyanide intoxication and its mechanism of antagonism. Annu. Rev. Pharmacol. Toxicol. 24, 451–481 (1984)

16 Isom, G.E., Burrows, G.E. and Way, J.L.: Effect of oxygen on the antagonism of cyanide intoxication—Cytochrome oxidase, in vivo. Toxicol. Appl. Pharmacol. 65, 250–255 (1982)

17 Shintomi, K., Egou, H., Tanaka, T., Itakura, T., Yoshimoto, K., Matsumoto, M. and Matsuoka, Y.: Pharmacological study of nicergoline (I): Protective effect against anoxic brain damages in animals. Folia Pharmacol. Japon. 87, 445–456 (1986) (Abs. in English)

18 Yasuda, H., Izumi, N., Nakanishi, M., Anami, K. and Maruyama, Y.: Pharmacological studies on Y-8894. (IV) Ameliorative effect on cerebral energy metabolic disorder induced by KCN. Folia Pharmacol. Japon. 88, 363–367 (1986) (Abs. in English)

19 Hoyer, S.: The effect of naftidrofuryl on cyanide-induced hypoxic damage to glucose and energy metabolism in brain cortex of rats. Arzneimittelforschung 34, 412–416 (1984)

20 Siesjo, B.K. and Ljunggren, B.: Cerebral energy reserves after prolonged hypoxia and ischemia. Arch. Neurol. 29, 400–407 (1973)

21 Kosterlitz, H.W., Peterson, S.J. and Robson, L.E.: Characterization of the ε-subtype of the opiate receptor in the guinea-pig brain. Br. J. Pharmacol. 73, 939–949 (1981)

22 Kameyama, T., Nabeshima, T., Yamaguchi, K., Kamata, K., Okuyama, S., Tsuji, H. and Sakakibara, S.: Pharmacological action of eptazocine (I-1,4-dimethyl-10-hydroxy-2,3,4,5,6,7-hexahydro-1,6-methano-1H-4-benzazepine). (III) Central action of eptazocine. Folia Pharmacol. Japon. 78, 629–645 (1981) (Abs. in English)

23 Carlsson, C., Harp, J.R. and Siesjo, B.K.: Metabolic changes in the cerebral cortex of the rat induced by intravenous pentothalsodium. Acta Anaesth. Scand. 57, Supp. 7–17 (1975)

24 Hein, H., Krieglstein, J. and Stock, R.: The effects of increased glucose supply and thiopental anesthesia on energy metabolism of the isolated perfused rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 289, 399–407 (1976)

25 Ueda, H., Hashimoto, T., Furuya, E., Tagawa, K., Kitagawa, K., Matsumoto, M., Yoneda, S., Kimura, K. and Kamada, T.: Changes in aerobic and anaerobic ATP-synthesizing activities in hypoxic mouse brain. J. Biochem. 104, 81–86 (1988)

26 Maekawa, T., Sakabe, T. and Takeshita, H.: Diazepam blocks cerebral metabolic and circulatory responses to local anesthetic-induced seizures. Anesthesiology 41, 389–391 (1974)

27 Yasuda, H., Nakanishi, M., Tsumagari, T., Nakajima, A. and Nakanishi, M.: The mechanism of action of a novel cerebral protective drug against anoxia I. The effect on cerebral energy demand. Arch. Int. Pharmacody. Ther. 242, 77–85 (1979)